Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 2c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11).

As of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Investing.com’s stocks of the week
• BMO Capital Reiterates Outperform Rating on CMS Energy (CMS)